[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355398-105":59,"doc-detail-355398-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","recent-highlights-and-breakthroughs-in-immunotherapy-for-head-and-neck-cancers-review-2025","Recent highlights and breakthroughs in immunotherapy for head and neck cancers - Review - 2025","","Review of recent advances in immunotherapy for head and neck oncology summarizes pivotal 2025 studies across major disease entities. Immune checkpoint inhibitors show clinically meaningful outcomes in mucosal squamous cell carcinoma, nasopharyngeal carcinoma, cutaneous squamous cell carcinoma, and BRAF V600E-mutated anaplastic thyroid carcinoma. The review also covers passive approaches targeting tumor-associated antigens, including antibody-drug conjugates and monoclonal or bispecific antibodies, reporting encouraging activity in heavily pretreated recurrent or metastatic settings. Overall, benefits emerge both with earlier ICI integration and with combinations that address resistance mechanisms or refine delivery.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/recent-highlights-and-breakthroughs-in-immunotherapy-for-head-and-neck-cancers-review-2025/355398/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/recent-highlights-and-breakthroughs-in-immunotherapy-for-head-and-neck-cancers-review-2025/355398.png","ImageObject",300,407,{"name":92,"@type":93},"Kyle","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main purpose of this review?","Question",{"text":113,"@type":114},"It highlights recent advances in immunotherapy for head and neck oncology, emphasizing pivotal early- and late-stage studies published or presented in 2025.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which treatment strategies are covered in this review?",{"text":118,"@type":114},"The review covers active immunotherapy (including immune checkpoint inhibitors, cancer vaccines, and oncolytic viruses) and passive immunotherapy (including monoclonal/bispecific antibodies, small molecules, adoptive cell therapy, and antibody-drug conjugates).",{"name":120,"@type":111,"acceptedAnswer":121},"What overall trends in results are summarized?",{"text":122,"@type":114},"Recent advances show a rapid increase in positive immunotherapy trials, with clinical benefit when checkpoint inhibitors are introduced earlier and when combined with agents targeting resistance or enabling more precise tumor delivery.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355398,1790194998,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":14,"preview_urls":147},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","REVIEW  \nUPRI RNIENTON Recent highlights and breakthroughs in  \nimmunotherapy for head and neck cancers  \nJoanna A. Vuille and Petr Szturz  \nPurpose of review  \nThis review highlights recent advances in immunotherapy for head and neck oncology, focusing on pivotal studies, both early-stage and late-stage, published or presented in 2025 .  \nRecent findings  \nNoteworthy results were reported with immune checkpoint inhibitors in mucosal squamous cell carcinoma of the head and neck (SCCHN) (KEYNOTE-689 and NIVOPOSTOP trials evaluating pembrolizumab and nivolumab, respectively, in the perioperative setting); in nasopharyngeal carcinoma (DIPPER and DIAMOND trials evaluating camrelizumab and toripalimab, respectively, in the curative setting with radiotherapy, and tagitanlimab in recurrent and/or metastatic disease); in cutaneous squamous cell carcinoma of the head and neck region (C-POST trial in the adjuvant setting and the combination of avelumab with cetuximab in the palliative setting); and in BRAF V600E-mutated anaplastic thyroid carcinoma (pembrolizumab with dabrafenib and trametinib) . Passive immunotherapy targeting tumor-associated antigens also showed encouraging activity in R/M-SCCHN (petosemtamab, ficerafusp-alfa, amivantamab, enfortumab vedotin) and in heavily pretreated R/M nasopharyngeal carcinoma (antibody-drug conjugates becotatug vedotin andizalontamab brengitecan [iza-bren]) .  \nSummary  \nRecent advances highlight a rapid surge in positive immunotherapy trials across different head and neck cancer entities, with clinical benefit observed both when immune checkpoint inhibitors are moved earlier in the disease course and when they are combined with agents targeting resistance mechanisms or enabling more precise drug delivery to tumors.  \nKeywords  \nanticancer antibodies, head and neck cancers, immune checkpoint inhibitors, immunotherapy  \nINTRODUCTION  \nImmunotherapy has become an essential pilar of oncologic treatment in the last two decades, radically changing the landscapes of some malignancies such as melanoma and pulmonary cancers. In the head and neck field as well, immunotherapy offers new treatment avenues which are being intensively studied.  \nThe field of immunotherapy encompasses a large range of tools related to the immune system, from specific molecules to sophisticated engineered cells. It can be conceptually divided into two main groups: active or passive immunotherapy, depending on its ability to integrate and collaborate with the patient's immune system. The modus operandi of active immunotherapy, including immune checkpoint inhibitors (ICIs), cancer vaccines and oncolytic viruses, relies on the activation of one's immune cells, thus boosting its recognition and/or active killing of tumor cells. On the other hand, passive immunotherapy is composed of preformed elements, whose immediate action on  \ntumor cells is independent of patient's immune system, such as monoclonal antibodies, bispecific antibodies, small molecules and adoptive cell therapy. Antibody-drug conjugates (ADCs) representing antibodies attached to a payload, allowing for a specific delivery of the chemotherapeutic drug, will be considered in this review as part of the passive immunotherapy. Emerging clinical data across both categories demonstrate meaningful anticancer activity.  \nMedical Oncology, Department of Oncology, University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), Lausanne, Switzerland Correspondence to Petr Szturz, MD, PhD, Lausanne University Hospital: Centre Hospitalier Universitaire Vaudois, Lausanne 1005, Switzerland. Tel: +41 21 314 01 55; e-mail: [szturz@gmail.com](szturz@gmail.com)  \n[Curr Opin Oncol](Curr Opin Oncol 2026)[ 2026](Curr Opin Oncol 2026), [38:201](38:201)–[211](211)  \n[DOI:10.1097/CCO.0000000000001211](DOI:10.1097/CCO.0000000000001211)  \nThis is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, a","cbCaidOy08tNuqip","https://ap.wps.com/l/cbCaidOy08tNuqip","pdf",224254,11,"English","# Purpose of review\n# Recent findings\n# Summary\n# Introduction\n# Active immunotherapy","[{\"question\":\"What is the main purpose of this review?\",\"answer\":\"It highlights recent advances in immunotherapy for head and neck oncology, emphasizing pivotal early- and late-stage studies published or presented in 2025.\"},{\"question\":\"Which treatment strategies are covered in this review?\",\"answer\":\"The review covers active immunotherapy (including immune checkpoint inhibitors, cancer vaccines, and oncolytic viruses) and passive immunotherapy (including monoclonal/bispecific antibodies, small molecules, adoptive cell therapy, and antibody-drug conjugates).\"},{\"question\":\"What overall trends in results are summarized?\",\"answer\":\"Recent advances show a rapid increase in positive immunotherapy trials, with clinical benefit when checkpoint inhibitors are introduced earlier and when combined with agents targeting resistance or enabling more precise tumor delivery.\"}]","Recent highlights and breakthroughs in immunotherapy for head and neck cancers - Review - 2025 | PDF",1790118502,28,[148,152],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/a928ae2791a89cb2cefe6901ec057b9e.webp",983,1303,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-08/feea3e53843c790df6256b589cfb8be7.webp",982,1301]